Atlas Trials

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

Clinical trial NCT02945046 · TERMINATED

Trial details

NCT number
NCT02945046
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Episodic Cluster Headache
Start date
2017-01-19
Primary completion
2019-05-13
Enrollment
169

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.